Embody

The $69 headline is the wrong place to start a trial

The current homepage leads with semaglutide at $69 and tirzepatide at $119 per month. The public one-month product pages instead show $79 and $129; twelve-month products cost $828 and $1,428. The purchase decision is therefore about a term as much as a price. Those annual totals are a substantial upfront commitment for someone who has yet to meet the care team.

Six-month products list $438 for semaglutide and $738 for tirzepatide. Six purchases at the one-month prices would total $474 or $774, a $36 difference in either case if those prices remain available. That saving seems modest beside the loss of flexibility. These are advertised purchase totals, not proof of six calendar months of medication or a personal prescription quote.

The homepage FAQ describes 4-, 12-, 24- and 52-week plans while the product titles use months. Establish the actual days of supply and charge dates before comparing another provider. Ask whether multiple shipments or a single delivery fulfill the selected term. A monthly-looking number cannot settle those questions.

Payment is the point of commitment

Embody generally makes payment nonrefundable, even if intake remains unfinished or treatment has not been used. Prepaid unused services and unshipped medication are included in that restriction. Waiting for tracking is therefore the wrong way to judge whether it is still easy to withdraw.

Provider-initiated medical disqualification permits a refund after deductions for used services, including clinician review. It is not an automatic full-refund promise.

The subscription renews automatically on the selected billing cycle until canceled; an annual purchase does not simply expire. Cancel through the portal, support email or phone at least 72 hours before renewal. Later requests can leave the next charge payable. The policy offers replacement for damaged or incorrect items. These are stated merchant rules, not a determination of every consumer’s legal rights.

That financial boundary drives my recommendation. A short plan limits the initial amount exposed to the policy, although it is still a purchase rather than a risk-free trial. Someone who needs the ability to change their mind after paying should resolve that requirement before enrolling.

Embody and JoinEm lead to the same care storefront

JoinEm is the website address used by the Embody-branded service. The terms name Modern Metabolic Medicine, doing business as Embody, and say the billing statement identifies Modern Metabolic Medicine, Inc. They separate the platform from independent clinicians, pharmacies and laboratories. The receipt and clinical consent should therefore identify the parties responsible for different parts of the purchase.

The public medical-consent footer identifies OpenLoop Health as the care network and describes a clinician deciding prescription eligibility after checkout. That is a named relationship, not independent verification of your assigned clinician or their state license. Ask which professional practice will provide your care and how to reach it for a medication concern.

Product pages warn that the program may not be available in every state. This review did not establish a complete current state list. Confirm your location and the particular preparation before payment; broad national-sounding marketing does not establish eligibility for an individual prescription.

Support promises need a clinical contact plan

The one-month semaglutide page includes clinician evaluation, prescription review, medication if appropriate, shipping, messaging support and dose adjustments. The homepage calls coaching optional and explains that coaches are not clinicians. Those roles can complement each other, but a helpful coach is not the person who decides a prescription change.

Before joining, establish how to contact the prescribing team, when a video consultation is needed and how long a clinical response normally takes. The public pages advertise round-the-clock support without establishing a universal clinician response deadline. An available message box and a rapid prescribing response are different services.

Lab services are described as applicable within the bundle, but this research did not establish a fixed required panel, testing schedule or a patient-specific lab charge. Get those details for your plan. The terms also retain a provision allowing the final charge to vary with medication and pharmacy, despite the fixed-price presentation. Ask how that provision applies before treating the advertised amount as unconditional.

Named pharmacies are useful; the assigned preparation still matters

The current catalog footer names Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx. That is more informative than an anonymous reference to partner pharmacies. It still does not tell you which location will dispense your order, what formulation you will receive or whether another partner could handle a refill. This review did not independently verify each pharmacy license.

The fourteen-product catalog contains compounded semaglutide and tirzepatide injection listings. It did not establish a current oral tirzepatide gum offer. Do not choose this program for a needle-free route without a specific current product and prescription explanation. Likewise, brand names appearing in safety materials are not proof that a branded product is available to purchase.

FDA advises using compounded GLP-1 drugs only when medical needs cannot be met by an approved medicine and obtaining them through a prescription and state-licensed pharmacy. Compounded preparations do not receive FDA premarket review for safety, effectiveness and quality. Discuss the reason for the selected preparation with the clinician rather than treating the low price as the whole decision. This general guidance is not an allegation of a provider-specific enforcement action.

Compare what an extra $10 buys before prepaying

Yucca’s public semaglutide monthly plan is $89, compared with Embody’s $79 one-month listing. Yucca’s refund policy allows cancellation and a full refund before a clinician issues the prescription, while Embody generally makes payment the boundary. That $10 difference purchases a different stated cancellation window, not evidence that one provider delivers better clinical care. Yucca also has restrictions after prescribing and on prepaid exits.

Embody belongs on a shortlist when the final amount, preparation and care arrangement satisfy your needs and its purchase policy is acceptable. I would begin with the shortest suitable term and reassess after understanding the service. The annual rate can wait; saving on an unused year is not a saving. This judgment comes from public offers and contracts checked October 25, 2026, without enrollment, treatment, delivery testing or a support interaction.